FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma
- Saturday, August 29, 2020, 7:02
- Finance
- Add a comment
STOCKHOLM, Aug. 29, 2020 /PRNewswire/ — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the US Food and Drug Administration, FDA, has granted priority review for Oncopeptides’ New Drug Application seeking approval of melflufen (INN melphalan flufenamide), in…
About the Author
adminasapcorp has written 39584 stories on this site.